Crocs (NASDAQ:CROX) Price Target Increased to $32.00 by Analysts at Zacks Investment Research
Other analysts have also recently issued reports about the company. Piper Jaffray Companies increased their price target on Crocs from $30.00 to $32.00 and gave the stock an overweight rating in a research report on Tuesday, September 17th. Robert W. Baird upgraded Crocs from a neutral rating to an outperform rating and set a $29.00 price target on the stock in a research report on Friday, June 21st. Susquehanna Bancshares increased their price target on Crocs from $35.00 to $38.00 and gave the stock a positive rating in a research report on Friday, August 2nd. Pivotal Research reiterated a buy rating on shares of Crocs in a research report on Friday, August 2nd. Finally, Stifel Nicolaus increased their price target on Crocs from $21.00 to $23.00 and gave the stock a hold rating in a research report on Friday, August 2nd. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $31.57.
Shares of NASDAQ CROX opened at $27.01 on Wednesday. The stock’s 50 day moving average price is $24.75 and its two-hundred day moving average price is $23.67. Crocs has a 52-week low of $17.52 and a 52-week high of $31.88. The stock has a market capitalization of $1.93 billion, a P/E ratio of 31.41, a PEG ratio of 1.30 and a beta of 0.99. The company has a quick ratio of 1.22, a current ratio of 1.74 and a debt-to-equity ratio of 3.03.
In other news, Director Doreen A. Wright sold 7,068 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $26.00, for a total transaction of $183,768.00. Following the sale, the director now directly owns 55,680 shares in the company, valued at approximately $1,447,680. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.42% of the stock is currently owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC raised its position in shares of Crocs by 15.4% during the 2nd quarter. Renaissance Technologies LLC now owns 3,855,300 shares of the textile maker’s stock worth $76,142,000 after purchasing an additional 513,900 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Crocs by 14.7% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 2,700,960 shares of the textile maker’s stock worth $53,344,000 after buying an additional 345,547 shares in the last quarter. Marshall Wace LLP grew its holdings in Crocs by 11.9% in the 2nd quarter. Marshall Wace LLP now owns 1,946,842 shares of the textile maker’s stock worth $38,450,000 after buying an additional 207,378 shares in the last quarter. Wells Fargo & Company MN grew its holdings in Crocs by 114.8% in the 2nd quarter. Wells Fargo & Company MN now owns 681,739 shares of the textile maker’s stock worth $13,464,000 after buying an additional 364,308 shares in the last quarter. Finally, Marshall Wace North America L.P. grew its holdings in Crocs by 47.2% in the 2nd quarter. Marshall Wace North America L.P. now owns 670,698 shares of the textile maker’s stock worth $13,247,000 after buying an additional 215,100 shares in the last quarter.
Crocs, Inc, together with its subsidiaries, designs, develops, manufactures, markets, and distributes casual lifestyle footwear and accessories for men, women, and children worldwide. It offers various footwear products, including clogs, sandals, flips and slides, shoes, and boots under the Crocs brand name.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crocs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crocs and related companies with MarketBeat.com's FREE daily email newsletter.